BJMO - 2021, issue 3, march 2021
Sofie Demasure , Isabel Spriet , Philip R. Debruyne , Annouschka Laenen , Wim Wynendaele , Marcella Baldewijns , Herlinde Dumez , Paul M. Clement , Hans Wildiers , Patrick Schöffski , Eduard Rousse , Lisa Kinget , Maarten Albersen , Benoit Beuselinck
Introduction: Only a limited number of recent phase III studies with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), mTOR-inhibitors or immune checkpoint inhibitors (ICI) in metastatic clear-cell renal cell carcinoma (m-ccRCC) could show an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS of m-ccRCC patients during the last 20-years period (2000–2020).
Read moreBJMO - 2021, issue 3, march 2021
Thomas Meyskens , Iris Timmermans , Hans Wildiers , Herlinde Dumez , Daphne Hompes , Melissa Christiaens , Raf Sciot , Annouschka Laenen , Jerry Lee , Patrick Schöffski
Objective: Angiosarcoma (AS) is a rare, aggressive subtype of soft tissue sarcoma (STS). Treatment requires a multidisciplinary approach and should preferably be carried out in reference centers. We performed an in-depth analysis of patient characteristics, treatments and prognostic factors in patients (pts) with AS treated at the University Hospitals Leuven (Belgium).
Read moreBJMO - volume 12, issue 3, february 2018
Y. Wang , A. Wozniak PhD, Jasmien Wellens , Y. Gebreyohannes , Maria Jose Guillén , C.M. Galmarini , Pablo M. Avilés , Maria Debiec-Rychter , Raf Sciot , Patrick Schöffski
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
